Key facts
- Flowbone’s last known valuation is $13.4M (Sep 2022).
- It has raised $4.8M; the latest was Later Stage VC ($2.5M) in Nov 2025.
- Notable investors include Venture Kick, Ecole Polytechnique Federale de Lausanne, Kickfund, EIT Health, Fondation pour l'Innovation Technologique — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Flowbone
- ·The full record, as it builds
Funding rounds
No funding rounds for Flowbone are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Flowbone
Developer of an injectable nanostructured biomaterial technology designed to stimulate the self-healing capabilities of the body to locally repair bone and restore its natural strength. The company's technology addresses the needs for minimally invasive surgical treatment of painful chronic insufficiency fractures, augmentation of fragile bones at high risk of fractures, and bone health optimization in spine surgery, enabling patients to enjoy an improved level of independence and quality of life, free from the impact of fragility fractures.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Employees
- 9
- Website
- flowbone.com/
- Ownership
- Privately Held (backing)
Flowbone doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Flowbone shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Flowbone in its N-PORT filings yet. We sweep new filings monthly.